What is non-relapsing secondary progressive MS?

Secondary progressive MS is the phase of multiple sclerosis in which the disease shifts from the relapsing-remitting pattern — attacks followed by partial or full recovery — to slow, continuous disability accumulation. In non-relapsing SPMS specifically, there are no acute relapses at all: the progression is continuous and uninterrupted. This is one of the hardest-to-treat forms of MS because most existing disease-modifying therapies work primarily by suppressing relapses and have limited effect on the underlying progressive trajectory.

Does tolebrutinib work for all forms of MS?

No. The HERCULES trial showed tolebrutinib significantly delayed disability progression in non-relapsing SPMS. A separate phase 3 trial in primary progressive MS (PPMS) found tolebrutinib did not meet its primary endpoint for that population. The TGA registration in Australia is specifically for non-relapsing SPMS in adults. Tolebrutinib is not registered for relapsing-remitting MS or primary progressive MS in Australia.

TGA approves tolebrutinib for progressive MS: what changes

What just happened

The Therapeutic Goods Administration has registered tolebrutinib (Cenrifki, Sanofi) for adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) — making it the first oral disease-modifying therapy approved in Australia specifically for this progressive form of the disease. For a population that has had almost no new treatment options for decades, this registration matters.

Multiple sclerosis affects roughly 33,000 Australians and, unlike most autoimmune conditions, disproportionately affects women at a ratio of approximately 3:1. Secondary progressive MS is the phase that follows the more widely recognised relapsing-remitting form. It is the point at which the disease trajectory shifts from unpredictable relapses toward slow, unrelenting disability accumulation. For many people living in that phase, the therapeutic toolkit largely runs out. Until now.

The pivotal evidence comes from the HERCULES phase 3 trial, which enrolled over 900 adults with confirmed nrSPMS. According to MS Australia’s coverage of the trial data, tolebrutinib significantly delayed the time to onset of confirmed disability progression compared to placebo. That is not a reversal of existing disability, and it is not a cure — but in a population where slowing the rate of progressive loss is the highest realistic clinical goal, it is a meaningful finding.

The both-and

This is a genuine advance in MS management for a specific, underserved population. It comes with important biological caveats and a substantial access gap.

What tolebrutinib does — and how it differs

Tolebrutinib is a BTK (Bruton’s tyrosine kinase) inhibitor. BTK is an enzyme involved in B-cell activation — B-cells are immune cells that play a significant role in the MS disease process. What distinguishes tolebrutinib from most existing disease-modifying therapies is that it is brain-penetrant: it crosses the blood-brain barrier and acts not only on peripheral B-cells but also on CNS-resident microglia. Microglia are the brain’s immune cells and are thought to be a key driver of the chronic, smouldering inflammation that underlies progressive disability accumulation in SPMS — the process that relapses-based therapies largely do not touch.

This dual mechanism — peripheral B-cell modulation plus CNS microglial engagement — is the biological rationale for why a BTK inhibitor might do something meaningful in progressive MS where previous agents have not. The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on tolebrutinib in April 2026, citing the HERCULES data as its basis — placing the TGA’s Australian registration in a global regulatory context where confidence in the nrSPMS data is converging.

Where it failed — and why that matters

Tolebrutinib is approved specifically for non-relapsing SPMS. A separate phase 3 trial in primary progressive MS (PPMS) did not meet its primary endpoint — the drug did not delay disability progression in that population. This is a clinically important distinction that the TGA registration reflects. PPMS and nrSPMS share the progressive label but differ in their underlying biology in ways that appear to matter for BTK inhibition. The reason one trial succeeded and the other did not is under active investigation.

For GPs: when a patient with PPMS asks about tolebrutinib, the honest answer is that the TGA registration does not cover them, and the evidence does not currently support its use in their specific diagnosis. This distinction needs to be communicated clearly.

The access problem

TGA registration clears the safety and efficacy gate. PBS listing clears the affordability gate. In Australia, these are two separate processes managed on separate timelines. The first regulatory approval of tolebrutinib in any jurisdiction dates to late 2025, and a PBAC evaluation and listing process typically takes 12 to 18 months from lodgement to decision. Without PBS listing, the out-of-pocket cost of a novel targeted biologic will be inaccessible to the overwhelming majority of patients. MS Australia has been active in advocating for an expedited PBAC pathway.

Until a listing is confirmed, TGA registration means: the drug is approved and can be prescribed — but most people with nrSPMS in Australia cannot afford it. That is the unresolved piece.

2 cents

If you or someone close to you has a confirmed diagnosis of secondary progressive MS with no current active relapses — nrSPMS specifically — this TGA registration is worth raising with your neurologist. Understanding whether you are a candidate, what the monitoring requirements of tolebrutinib involve, and where it sits relative to your current management plan are conversations worth having now, ahead of PBS listing, not after.

The general practice role here is primarily support and information: knowing that tolebrutinib exists, understanding that it is for nrSPMS specifically (not PPMS, not relapsing-remitting MS), and being able to explain why PBS access is not yet available. That context, given calmly and accurately to a patient who has just read a headline, is genuinely useful.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

The TGA registration of tolebrutinib for nrSPMS is the first genuinely new treatment option for this form of progressive MS in Australia. The HERCULES trial data is meaningful, the brain-penetrant BTK mechanism is a plausible step forward in targeting progressive disease biology, and the access gap — pending PBS listing — is the next critical watch point. For a condition that predominantly affects women and has had so few therapeutic advances, this registration is news that matters.